Announcement of Establishment of a Holding Company in the U.S.

TOKYO, June 26, 2009--The Company announces that at its meeting held on June 26, the Board of Directors decided to establish a wholly-owned company (a holding company) in the United States in July this year as follows:

1. Purposes and an outline of the holding company The Company has been promoting a business development in the United States with emphasis on development and launching of “lurasidone”, which is under clinical development for schizophrenia, under the Mid-term Business Plan which aims at full formation and enhancement of the business foundation toward the Company’s globalization. A wholly-owned holding company has been decided to be established in the U.S. as part of the Mid-term Business Plan.

In the United States, Dainippon Sumitomo Pharma America, Inc. (DSPA), the Company’s wholly-owned U.S. firm, is now forwarding global development of lurasidone as well as preparation for building of a selling system for this particular product. DSPA is going to be a 100%-owned subsidiary of this holding company. A new sales subsidiary is also planned to be formed under the holding company in the future.

3. Way of capitalization The Company contributes $22,400,000 in cash and $600,000 in kind (DSPA shares) to the holding company, and the holding company simultaneously transfers $21,400,000 to DSPA in the form of capital increase of DSPA.

4. Impact on financial results of the Company Slight impact is given by formation of the holding company to financial results of the Company.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.